Log in | Register

Home
All Journals
Expert Opinion on Investigational Drugs
List of Issues
Volume 31, Issue 4

Expert Opinion on Investigational Drugs

Search in:

Advanced search Citation search

Citation search

Ready to submit?
Start a new submission or continue a submission in progress
Go to submission site
Instructions for authors
Editorial policies
Editing services site

Journal metrics
Aims & scope
Journal information
Editorial board
News & calls for papers
Advertising information

Latest articles
Current issue
All volumes & issues
Special issues
Open access articles
Most read articles
Most cited articles

New content alerts
RSS

Subscription options & pricing

Buy a subscription

Your download is now in progress and you may close this window

Did you know that with a free Taylor & Francis Online account you can gain access to the following benefits?

Choose new content alerts to be informed about new research of interest to you
Easy remote access to your institution's subscriptions on any device, from any location
Save your searches and schedule alerts to send you new results
Export your search results into a .csv file to support your research

Have an account?
Login now Don't have an account?
Register for free

Login or register to access this feature

Have an account?
Login now Don't have an account?
Register for free

Register a free Taylor & Francis Online account today to boost your research and gain these benefits:

Choose new content alerts to be informed about new research of interest to you
Easy remote access to your institution's subscriptions on any device, from any location
Save your searches and schedule alerts to send you new results
Export your search results into a .csv file to support your research

Register now or learn more

Expert Opinion on Investigational Drugs, Volume 31, Issue 4 (2022)

Browse this journal

Latest articles
Current issue
List of issues
Special issues
Open access articles
Most read articles
Most cited articles

Sample our Medicine, Dentistry, Nursing & Allied Health journals, sign in here to start your FREE access for 14 days

Expert Opinion on Investigational Drugs, Volume 31, Issue 4 (2022)

See all volumes and issues

Vol 33, 2024 Vol 32, 2023 Volume 31, 2022 Vol 30, 2021 Vol 29, 2020 Vol 28, 2019 Vol 27, 2018 Vol 26, 2017 Vol 25, 2016 Vol 24, 2015 Vol 23, 2014 Vol 22, 2013 Vol 21, 2012 Vol 20, 2011 Vol 19, 2010 Vol 18, 2009 Vol 17, 2008 Vol 16, 2007 Vol 15, 2006 Vol 14, 2005 Vol 13, 2004 Vol 12, 2003 Vol 11, 2002 Vol 10, 2001 Vol 9, 2000 Vol 8, 1999 Vol 7, 1998 Vol 6, 1997 Vol 5, 1996 Vol 4, 1995 Vol 3, 1994

Select to download all citations or PDFs

Download citations Download PDFs Download issue

Browse by section (All)

Display order (Default)
Published online date
Page number
Section A-Z
Most read
Most cited

Hepatocellular carcinoma

Foreword

Editorial

Foreword: hepatocellular carcinoma: emerging treatments, drug targets, and fundamental knowledge gaps

Alessandro Rizzo & Gennaro Palmiotti

Page: 331

Published online: 02 Mar 2022

CitationforForeword: hepatocellular carcinoma: emerging treatments, drug targets, and fundamental knowledge gaps | Full Text | PDF (106.7 KB) | EPUB

1324 Views
0 CrossRef citations
0Altmetric

Free Access

Editorial

Tyrosine kinase inhibitors plus immune checkpoint inhibitors as neoadjuvant therapy for hepatocellular carcinoma: an emerging option?

Alessandro Rizzo

Pages: 333-335

Published online: 05 Jul 2021

First Page PreviewforTyrosine kinase inhibitors plus immune checkpoint inhibitors as neoadjuvant therapy for hepatocellular carcinoma: an emerging option? | Full Text | References | PDF (606.6 KB) | EPUB

1832 Views
0 CrossRef citations
0Altmetric

Free Access

Drug Evaluation

Article

Camrelizumab: an investigational agent for hepatocellular carcinoma

Bin Xu & Hui-Chuan Sun

Pages: 337-346

Published online: 28 Dec 2021

AbstractforCamrelizumab: an investigational agent for hepatocellular carcinoma | Full Text | References | PDF (334.5 KB) | EPUB

389 Views
3 CrossRef citations
0Altmetric

Article

Durvalumab: an investigational agent for unresectable hepatocellular carcinoma

Marta Maestri, Maria Pallozzi, Francesco Santopaolo, Lucia Cerrito, Maurizio Pompili, Antonio Gasbarrini & Francesca Romana Ponziani

Pages: 347-360

Published online: 09 Feb 2022

AbstractforDurvalumab: an investigational agent for unresectable hepatocellular carcinoma | Full Text | References | PDF (411.9 KB) | EPUB

393 Views
7 CrossRef citations
0Altmetric

Article

Atezolizumab-bevacizumab plus Y-90 TARE for the treatment of hepatocellular carcinoma: preclinical rationale and ongoing clinical trials

Alessandro Di Federico, Alessandro Rizzo, Riccardo Carloni, Andrea De Giglio, Riccardo Bruno, Dalia Ricci & Giovanni Brandi

Pages: 361-369

Published online: 01 Dec 2021

AbstractforAtezolizumab-bevacizumab plus Y-90 TARE for the treatment of hepatocellular carcinoma: preclinical rationale and ongoing clinical trials | Full Text | References | PDF (1.1 MB) | EPUB

975 Views
30 CrossRef citations
0Altmetric

Perspective

Article

Lenvatinib plus pembrolizumab: the next frontier for the treatment of hepatocellular carcinoma?

Alessandro Rizzo, Vincenzo Dadduzio, Angela Dalia Ricci, Francesco Massari, Alessandro Di Federico, Gennaro Gadaleta-Caldarola & Giovanni Brandi

Pages: 371-378

Published online: 30 Jun 2021

AbstractforLenvatinib plus pembrolizumab: the next frontier for the treatment of hepatocellular carcinoma? | Full Text | References | PDF (1.4 MB) | EPUB

844 Views
48 CrossRef citations
0Altmetric

Review

Combination therapies plus transarterial chemoembolization in hepatocellular carcinoma: a snapshot of clinical trial progress

Zachary J. Brown, D Brock Hewitt & Timothy M Pawlik

Pages: 379-391

Published online: 25 Nov 2021

AbstractforCombination therapies plus transarterial chemoembolization in hepatocellular carcinoma: a snapshot of clinical trial progress | Full Text | References | PDF (1.4 MB) | EPUB

737 Views
3 CrossRef citations
0Altmetric

FGFR4 inhibitors for the treatment of hepatocellular carcinoma: a synopsis of therapeutic potential

Hao Xie, Diego M Alem Glison & Richard D. Kim

Pages: 393-400

Published online: 20 Dec 2021

AbstractforFGFR4 inhibitors for the treatment of hepatocellular carcinoma: a synopsis of therapeutic potential | Full Text | References | PDF (1 MB) | EPUB

374 Views
3 CrossRef citations
0Altmetric

Cabozantinib plus atezolizumab for the treatment of advanced hepatocellular carcinoma: shedding light on the preclinical rationale and clinical trials

Antonella Cammarota, Valentina Zanuso, Antonio D’Alessio, Tiziana Pressiani, Nicola Personeni & Lorenza Rimassa

Pages: 401-413

Published online: 10 Feb 2022

AbstractforCabozantinib plus atezolizumab for the treatment of advanced hepatocellular carcinoma: shedding light on the preclinical rationale and clinical trials | Full Text | References | PDF (1.8 MB) | EPUB

482 Views
6 CrossRef citations
0Altmetric

PD-L1, TMB, and other potential predictors of response to immunotherapy for hepatocellular carcinoma: how can they assist drug clinical trials?

Alessandro Rizzo & Angela Dalia Ricci

Pages: 415-423

Published online: 30 Aug 2021

AbstractforPD-L1, TMB, and other potential predictors of response to immunotherapy for hepatocellular carcinoma: how can they assist drug clinical trials? | Full Text | References | PDF (2.3 MB) | EPUB

532 Views
70 CrossRef citations
0Altmetric

The dual checkpoint blockade in unresectable hepatocellular carcinoma: opportunities emerging in clinical trials

Antonella Cammarota, Valentina Zanuso, Antonio D’Alessio, Tiziana Pressiani, Silvia Bozzarelli, Nicola Personeni & Lorenza Rimassa

Pages: 425-435

Published online: 22 Feb 2022

AbstractforThe dual checkpoint blockade in unresectable hepatocellular carcinoma: opportunities emerging in clinical trials | Full Text | References | PDF (1.5 MB) | EPUB

432 Views
1 CrossRef citations
0Altmetric

Explore articles

Latest
Open access
Most read
Most cited
Trending

Explore the most recently published articles

Inflammation and Huntington’s disease- a neglected therapeutic target?

Sophie E. Field et al.

Review Article | Published online: 17 May 2024

Drugs in preclinical and early clinical development for the treatment of Chagas´s disease: the current status

Fernanda Karoline Vieira da Silva Torchelsen et al.

Review Article | Published online: 14 May 2024

Emerging therapies for overactive bladder: preclinical, phase I and phase II studies

Samantha Gibson et al.

Review Article | Published online: 9 May 2024

Frontotemporal dementia: from genetics to therapeutic approaches

Francesca R. Buccellato et al.

Review Article | Published online: 9 May 2024

Open Access

View all latest articles

Download citations

Choose format

RIS (ProCit, Reference Manager)
BibTeX
RefWorks Direct Export

Download citations

Expert Opinion on Investigational Drugs (Vol.31, Iss.4, 2022)

Hepatocellular carcinoma

Hepatocellular carcinoma

Access Rights

Only articles that you have access rights to view will be downloaded. The green tick (full access) and orange padlock (open access) icons indicate that you have full access.

Do you want to proceed?